Booster Therapeutics is pioneering a novel class of medicines aimed at enhancing the activity of the 20S proteasome, a critical component of the cell's natural quality control system. Unlike traditional protein degradation therapies that focus on tagging specific proteins for degradation via ubiquitin, Booster's approach seeks to restore the overall functionality of the proteasome. This is particularly important as proteasome dysfunction can lead to the accumulation of damaged and misfolded proteins, contributing to various complex diseases, especially neurodegenerative conditions. By directly activating the 20S proteasome, Booster's small molecules can recognize and degrade a wide range of disease-associated proteins without the need for prior tagging, thereby promoting cellular resilience and maintaining protein homeostasis.

The company employs its proprietary DGRADX™ platform, which integrates advanced techniques such as automated high-throughput screening and X-ray crystallography, to discover and develop activator compounds with therapeutic potential. This innovative approach not only aims to restore proteasome function but also addresses the broader implications of proteasome dysfunction in aging and disease. By focusing on a multi-disease pipeline, particularly in neurodegenerative diseases, Booster Therapeutics is positioned to make significant advancements in treating conditions that arise from impaired cellular quality control mechanisms.

Germany

Booster Therapeutics is pioneering a new class of medicines that activate proteasomes (the cell’s natural quality control machinery) to treat a range of complex indications. The company is developing a multi-disease pipeline, with an initial focus on neurodegenerative diseases associated with impaired proteasome function.

Booster Therapeutics

Company Details